Antiphospholipid antibodies in asymptomatic pediatric patients;Anticuerpos antifosfolípido en población pediátrica asintomática

Anales Espanoles de Pediatria

Volumn 54, Issue 5, 2001, Pages 444-449

  Aguilar Franco, C ^a   Lucia Cuesta J F ^a  

^a Hospital General del Insalud Soria   (Spain)

Author keywords

Antiphospholipid antibodies; Children; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 12; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADENOIDECTOMY; ANTIBODY DETECTION; ARTICLE; BLOOD CLOTTING FACTOR 12 DEFICIENCY; CHILD; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEDICAL SOCIETY; PARTIAL THROMBOPLASTIN TIME; TONSILLECTOMY; VIRUS INFECTION;

ADENOIDECTOMY; ANTIBODIES, ANTIPHOSPHOLIPID; CHILD; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; PARTIAL THROMBOPLASTIN TIME;

EID: 0035745326     PISSN: 03024342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Thrombosis, abortion, cerebral disease and the lupus anticoagulant
2. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta2 glycoprotein I (apolipoprotein H)
3. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
4. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenetic mechanism?
5. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes
6. Antiphospholipid antibodies: Specificity and pathophysiology
7. Anticardiolipin antibodies and the risk for ischemic stroke and venous thromboembolism
8. Antiphospholipid thromboses: Clinical course after the first thrombotic event in 70 patients
9. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four year prospective study from the Italian registry
10. Anticardiolipin olipin antibodies: Clinical consequences of "low titers"
11. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects
12. Lupus anticoagulant in children with thrombosis
13. Lupus anticoagulants in children
14. Criteria for the diagnosis of lupus anticoagulants: An update
15. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies
16. The use of dilute Russell viper venom time for the diagnosis of lapus anticoagulants
17. A new lupus anticoagulant neutralization test based on platelet-derived vesicles
18. A hexagonal (11) phase phospholipid neutralization assay for lupus anticoagulant identification
19. Measurement of anticarcdiolipin antibodies by an enzyme linked immunosorbent assay: Standardization and quantitation of results
20. The risk of thrombosis in patients with lupus anticoagulant is predicted by their specific coagulation profile
21. Childhood thrombosis
22. Lupus anticoagulant in children
23. Preoperative history and coagulation screening in children undergoing tonsillectomy
24. Utilidad de las pruebas preoperatorias de coagulación en la prevención de la hemorragia post-amigdalectomía en niños
25. Antiphospholid antibodies in children
26. Hypoprothrombinaemia and severe hemorrhage associated with lupus anticoagulant
27. Autoantibodies and common viral illnesses
28. Binding profiles of anticardiolipin antibodies in sera from patients with SLE and infectious diseases
29. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children
30. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis
31. Anti-beta2 glycoprotein I antibodies: Detection and association with thrombosis
32. 2-glycoprotein I in patients with antiphospholipid syndrome
33. 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assay
34. 2-glycoprotein I-dependent antiphospholipid antibodies
35. The lupus anticoagulant: High incidence of negative mixing studies in a human immunodeficiency virus-positive population
36. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: An analysis of results from three surveys of the UK National Assessment Scheme (NEQAS) for Blood Coagulation
37. Factor XII determinations in the presence and absence of phospholipid antibodies
38. Pseudo factor XII deficiency and phospholipid antibodies
39. Antibodies to factor XII associated to lupus anticoagulant